Compare Danaher Corporation (DHR) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Schwab US Dividend Equity ETF — how do they compare? Danaher Corporation trades at $220.03 (market cap $152.87B), while Schwab US Dividend Equity ETF trades at $33.07 (market cap $110.56B). The key difference: Danaher Corporation is the larger of the two by market cap, and Danaher Corporation pays a 0.74% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| DHR | SCHD | |
|---|---|---|
Market Cap | $152.87B | $110.56B |
Volume | 5,228,698 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $242.05 | $35.21 |
52-Week Low | $161.91 | $26.44 |
Typical Hold Time | 69 Days | 62 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
SCHD trades at $33.06, up 1.26% today, with a bullish technical signal despite mixed moving averages. The ETF has outperformed the S&P 500 in 2026, with recent news highlighting its dividend growth and defensive positioning. Key support sits at $32 with resistance at $34, while oscillators show neutral momentum. The fund's rules-based approach focuses on high-quality dividend stocks, though recent exclusions like Broadcom have sparked discussion about opportunity costs.
SCHD offers income investors exposure to rising dividends with lower fees, but faces headwinds from interest rate sensitivity and strict selection criteria that may limit growth participation. The current pullback from August highs near $35 presents a potential entry point for dividend-focused portfolios seeking quality and yield sustainability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
